Why are Medicare and Medicaid shown separately instead of combined?

They come from two different CMS data sources with no shared claim identifier, so they can't be reconciled into one number without double-counting or guessing. Every table and chart on this page keeps them fully separate.

Why is there no private/commercial revenue figure?

Private and commercial payer data comes from Transparency in Coverage files, which only publish negotiated rates — not claims or utilization volume. Without a volume figure, no revenue number can be computed for any provider from that data.

What does "Rank" mean in the Competitive Analysis & Benchmarks tables?

For a given CPT/HCPCS code, it's this provider's position by claims volume among all providers billing that same code at that geography level (State, National, or Virginia for Medicaid) — rank 1 means the highest claims volume for that code.

Why is the Medicaid comparison limited to Virginia only?

Medicaid is administered per-state with no single national fee schedule, so a state or national comparison the way Medicare has one isn't available. Virginia (this provider's own state) is the only grouping that's conceptually meaningful.

Why are the numbers rounded to the nearest 10?

To avoid implying more precision than the underlying data supports at a single-provider level. Ratios are kept precise since they're a relative comparison, not a volume or dollar figure.

How current is this data?

The Medicare and Medicaid tables are both single current snapshots, not refreshed on a recurring schedule yet.

Jong An (NPI 1043419096)

Field	Value
Entity Type	Individual
Organization	Jong An
Address	1701 Thomson Dr Ste 200
City	Lynchburg
State	VA
ZIP	24501
Taxonomy	Hematology & Oncology Physician
NPI Enumerated	July 11, 2007

Payer Source	Total Paid
Medicare	$2.4M
Medicaid	$0

Key Findings

This provider reports $2.4M in total Medicare revenue and has no Medicaid billing on file, making their commercial and Medicaid exposure effectively nil in the available data. The absence of any Medicaid claims suggests the provider is functionally single‑payer (Medicare) for the billing observed, which concentrates reimbursement risk and negotiation leverage around Medicare rates and coverage policies rather than a mixed‑payer footprint.

Revenue concentration is high: the precomputed top 3 Medicare codes by revenue account for 57.1% of this provider's total Medicare revenue, indicating that a small set of infused oncology agents drives the majority of billing. Those top codes include J9299 ($554.9K, 23.1K claims), J9271 ($510.4K, 11.6K claims), and J0897 ($216K, 12K claims), so product mix and drug pricing dynamics will materially affect overall revenue.

The code mix and volumes point to an oncology infusion practice focused on immune checkpoint inhibitors and supportive bone-modifying therapy: J9299 (nivolumab) and J9271 (pembrolizumab) are the two largest revenue contributors, and J0897 (denosumab) is the third. In addition to high-cost biologics, the provider bills chemotherapy administration codes (96413, 96367) and supportive agents (J2506 pegfilgrastim, Q5106 epoetin biosimilar), consistent with a full-service hematology/oncology infusion suite treating both solid tumor and hematologic indications.

Competitive standing on key immunotherapy codes is modest to typical nationally: J9299 ranks #126 of 505 providers (75th percentile) and is labeled typical/unremarkable volume, while J9271 ranks #990 of 1841 providers (45th percentile) and is also typical/unremarkable. By contrast, J0897 ranks #832 of 10057 providers (92th percentile) and—despite the dataset labeling it typical/unremarkable—this rank places the provider well above many peers in denosumab utilization, signaling a comparatively strong footprint for bone‑targeted supportive care.

Several utilization signals are notable for being above typical national volumes: office E/M 99214 ranks #19437 of 479517 (96th percentile) and is described as notably above typical national volume, and chemotherapy administration 96413 ranks #566 of 7514 (92th percentile) with the same characterization. The provider also shows a high relative volume for additional infusion work‑up code 96367 (771 claims; 97th percentile; notably above typical), which together indicate heavier-than-average procedural throughput in infusion and oncology clinic workflows.

There are procedural and lab volumes that suggest substantial on-site outpatient support services: 36415 (blood draw) has 1.7K claims and ranks #1200 of 86467 providers (99th percentile, typical/unremarkable), and 85025 (CBC) and 80053 (CMP) appear in the top codes with high national percentiles. These patterns imply the practice performs most routine lab monitoring and phlebotomy in-house, consistent with an infusion center model that manages ongoing patient monitoring alongside drug administration.

The provider participates in billing of several biosimilars and newer agents but in small national cohorts for some products: Q5126 (bevacizumab biosimilar) is billed ($60.5K) and the provider ranks #29 of 29 nationally (0th percentile), and Q5112 (trastuzumab biosimilar) appears with $21.5K and rank #6 of 6 (0th percentile). These ranks indicate the provider is among a very small number of national billers for those specific HCPCS entries, which may reflect local adoption patterns, contracting choices, or coding of biosimilar variants.

Tenure and specialty profile support clinical experience: the provider's NPI was enumerated 2007-07-11 (~19 years ago) and taxonomy is Hematology & Oncology Physician, aligning with the observed drug- and procedure-heavy oncology billing mix. That length of enrollment combined with the concentration in high-cost infused agents suggests an established oncology practice with an operational reliance on Medicare infusion reimbursement streams.

Medicare: Complete Services Breakdown

The CPT/HCPCS codes generating the most Medicare revenue for this provider.

90 rows

CPT/HCPCS Code	Description	Claims	Avg Paid	Revenue
J9299	Injection, nivolumab, 1 mg	23,120	$20	$554.9K
J9271	Injection, pembrolizumab, 1 mg	11,600	$40	$510.4K
J0897	Injection, denosumab, 1 mg	12,000	$20	$216K
J9144	Injection, daratumumab, 10 mg and hyaluronidase‑fihj	3,420	$40	$130K
J1930	Injection, lanreotide, 1 mg	2,880	$50	$129.6K
J1569	Injection, immune globulin, (gammagard liquid), non-lyophilized, (e.g., liquid), 500 mg	2,710	$40	$97.6K
J1439	Injection, ferric carboxymaltose, 1 mg	75,750	$1	$75.8K
99214	The provider sees an established patient for an office visit or other outpatient visit involving evaluation and management. The visit involves a moderate level of medical decision making, and/or the…	800	$90	$71.4K
Q5126	Injection, bevacizumab-maly, biosimilar, (alymsys), 10 mg	1,100	$60	$60.5K
J9264	Injection, paclitaxel protein-bound particles, 1 mg	5,900	$10	$59K

Showing 1–10 of 90

Medicare: Competitive Analysis & Benchmarks

How this provider's Medicare billing volume and revenue compare to other providers nationally and within its state, across 90 CPT/HCPCS codes.

View: State1 / 2

Claims Volume vs. Virginia Distribution

Jong An — 3 of 25 codes billed far more than typical (above p95)

p5–p95 (all providers)p25–p75MedianThis providerOutlier

Rank Distribution — Virginia

Full comparison — all codes billed, vs. state median

90 rows

CPT/HCPCS Code	Rank	Provider Count	Median Claims	Avg Paid	Average Revenue
J9271	10	110	12,800	$40	$610.9K
J9299	1	30	12,920	$20	$335.4K
J9144	10	60	8,280	$40	$332.7K
Q5126	2	10	4,930	$50	$247.2K
J1930	2	10	3,840	$40	$188.7K
J1569	8	30	3,000	$40	$135.7K
J0897	17	340	2,820	$20	$89.3K
J9264	1	10	6,800	$10	$86.1K
Q5119	2	40	1,570	$20	$39.6K
88185	3	60	620	$20	$34.3K

Showing 1–10 of 90

Related Providers

Other providers that share a Tax Identification Number (TIN) with Jong An, ranked by combined Medicare and Medicaid revenue.

Provider	State	Taxonomy	Medicare Revenue	Medicaid Revenue
Centra Medical Group, LLC	VA	Family Medicine Physician	$0	$60.1M
Columbus Radiology Corp	OH	Diagnostic Radiology Physician	$0	$49.9M
Robert Brennan	VA	Infectious Disease Physician	$15.9M	$0
Danville Physician Practices LLC	VA	Anesthesiology Physician	$0	$13M
Lakshminarayanan Nandagopal	VA	Hematology & Oncology Physician	$2.9M	$0
Charles Maurer	VA	Hematology & Oncology Physician	$2.8M	$0
Bonny Moore	VA	Hematology & Oncology Physician	$2.7M	$0
Matthew Whitehurst	VA	Medical Oncology Physician	$2.1M	$0
Christopher Vaughn	VA	Hematology & Oncology Physician	$2M	$0
Sudeep Menachery	VA	Hematology & Oncology Physician	$1.9M	$0

Nearby Providers

Other providers in the same ZIP code as Jong An, ranked by combined Medicare and Medicaid revenue.

Provider	State	Taxonomy	Medicare Revenue	Medicaid Revenue
Lutheran Family Services Of Virginia, Inc.	VA	Intellectual and/or Developmental Disabilities Community Based Residential Treatment Facility	$0	$194.3M
Horizon Behavioral Health	VA	Community/Behavioral Health Agency	$0	$138.1M
Brightview LLC	VA	Substance Use Disorder Rehabilitation Clinic/Center	$0	$32M
Centra Health Inc	VA	General Acute Care Hospital	$0	$18.5M
Virginia Treatment Center, LLC	VA	Methadone Clinic	$116.5K	$15.9M
Cabaniss Consultants LLC	VA	Developmentally Disabled Services Day Training Agency	$0	$10.9M
Sense Of Security Care, Inc.	VA	Home Health Aide	$0	$9.2M
Surgery Center Of Lynchburg LLC	VA	Ambulatory Surgical Clinic/Center	$4M	$799.8K
Landon Colling	VA	Ophthalmology Physician	$2.8M	$190
Pathology Consultants Of Central Va, Inc	VA	Clinical Medical Laboratory	$696K	$1.6M

Jong An — Billing Profile & Reimbursement Data

Sign up for Jong An — Billing Profile & Reimbursement Data policy alerts

Jong An — Billing Profile & Reimbursement Data

Sign up for Jong An — Billing Profile & Reimbursement Data policy alerts

Key Findings

Medicare: Total Revenue Breakdown by CPT/HCPCS Code

Medicare: Complete Services Breakdown

Medicare: Competitive Analysis & Benchmarks

Related Providers

Nearby Providers

Frequently Asked Questions

References